| Heading: |
Drugs: Fees and Charges |
| Question ID: |
1819881 |
| UIN: |
HL9139 |
| House: |
Lords |
| Date tabled: |
2025-07-04 |
| Asking Member ID: |
4130 |
| Asking Member display name: |
Baroness Ritchie of Downpatrick
|
| Asking Member handle: |
MRitchieSD
|
| Asking Member Twitter reference: |
@MRitchieSD
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what steps they are taking to ensure that the pricing and reimbursement of multi-indication medicines does not deter future investment in UK-based research and development or the launches of new medicines. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-08-12 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
In January 2025, following public consultation, NHS England published an updated NHS Commercial Framework for New Medicines. This framework includes the approach for assessing the eligibility for medicines that may treat multiple indications to qualify fo... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |